Azitra, INC 8-K filings

Azitra, Inc. announced its Q2 2026 financial results, highlighting preclinical data for ATR-COSF, continued enrollment in ATR-04 trials, and expansion into recombinant protein initiatives.

Azitra, Inc. reported promising ex vivo human skin tissue study results for its ATR-COSF program, demonstrating increased distribution and anti-wrinkle effects.

Azitra, Inc. announces a strategic reorientation towards cosmetic ingredients and biotechnology products, leveraging its microbial genetic engineering platform and recent financing.

Azitra, Inc. announced the results of its reconvened 2026 annual meeting of stockholders, where key proposals including an increase in authorized common stock were approved.

Azitra, Inc. has adjourned its 2026 Annual Meeting of Stockholders to June 15, 2026, due to an insufficient number of shares present to constitute a quorum.

Azitra, Inc. has announced the adjournment of its 2026 Annual Meeting of Stockholders to June 15, 2026, due to a minor administrative delay in mailing proxy materials.

Azitra, Inc. announced a private placement financing of up to $31.4 million, with an initial $10.5 million, to fund new cosmetic and cosmeceutical research programs.

Azitra, Inc. received a notice from NYSE American for non-compliance with minimum stockholders' equity requirements, risking delisting despite an accepted compliance plan.

Azitra, Inc. announced the cancellation of its special meeting of stockholders after failing to achieve a quorum at its initial and adjourned sessions.

Azitra, Inc. announced its full year 2025 financial results and provided updates on its clinical-stage dermatology programs, including progress in trials for Netherton Syndrome and EGFRi-associated rash.

Azitra, Inc. adjourned its Special Meeting of stockholders due to a lack of quorum, postponing a crucial vote on a significant share issuance related to a capital raise until March 6, 2026.

Azitra, Inc. announced that NYSE American accepted its plan to regain compliance with minimum stockholders' equity requirements, granting a plan period until April 1, 2027.

Azitra, Inc. announced a private placement offering of $1.5 million, selling common stock and warrants to a single institutional investor at a premium to market.

Azitra, Inc. announced its third-quarter 2025 financial results, highlighting progress in its clinical-stage dermatology programs and a recent capital raise.

Azitra, Inc. received a notice from NYSE American for non-compliance with continued listing standards due to insufficient stockholders' equity and a history of losses.

Azitra, Inc. has modified its $20 million equity line of credit agreement with Alumni Capital LP, introducing new pricing options for future common stock purchases.

Azitra, Inc. will implement a 1-for-6.66 reverse stock split of its common stock effective August 21, 2025, to consolidate shares.

Azitra, a clinical stage biopharmaceutical company, announced its Q2 2025 financial results, highlighted by progress in its ATR-12 and ATR-04 clinical programs and a new $20 million equity line of credit.

Azitra, Inc. stockholders approved an amendment to increase the authorized number of common stock shares from 100 million to 200 million, effective July 3, 2025.

Azitra, Inc. announced that its stockholders approved the election of four directors and the ratification of its independent accounting firm, while adjourning a vote on increasing authorized common stock until July 3, 2025.

Azitra, Inc. has filed a supplement to its proxy statement, updating the voting standard for a proposal to increase its authorized common stock from 100 million to 200 million shares, aligning with recent Delaware law changes.

Azitra, Inc. announced promising safety and tolerability data from the initial Phase 1b clinical trial of its therapeutic candidate ATR12-351 for Netherton syndrome, with no severe adverse events reported.

Azitra, Inc. reported its Q1 2025 financial results, highlighted by progress in clinical trials for ATR-12 and ATR-04, and the closing of public offerings raising $2.2M.

Azitra, Inc. announces the date for its 2025 Annual Meeting of Stockholders and establishes deadlines for shareholder proposals and director nominations.

Azitra, Inc. has entered into a share purchase agreement with Alumni Capital LP for up to $20 million to fund the development of its precision dermatology therapies.

Azitra, Inc., a clinical-stage biopharmaceutical company, announced its full-year 2024 financial results and provided a business update, highlighting progress in its clinical programs and financial activities.

Azitra Inc. stockholders approved a reverse stock split amendment and a proposal to adjourn the special meeting if necessary, during a special meeting held on February 20, 2025.

Azitra, Inc. issues warrants to purchase common stock and grants participation rights in future financings to investors in connection with a previously disclosed common stock offering.

Azitra, Inc. has entered into a securities purchase agreement for a registered direct offering of common stock, expected to generate approximately $930,000 in gross proceeds.

Azitra, Inc. has successfully priced a public offering of common stock, raising approximately $1.5 million to support its clinical-stage biopharmaceutical programs.